Exploring the NK cell platform for cancer immunotherapy

Jacob A. Myers, Jeffrey S. Miller

Research output: Contribution to journalReview articlepeer-review

588 Scopus citations


Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system that are capable of killing virally infected and/or cancerous cells. Nearly 20 years ago, NK cell-mediated immunotherapy emerged as a safe and effective treatment approach for patients with advanced-stage leukaemia. Subsequently, the field of NK cell-based cancer therapy has grown exponentially and currently constitutes a major area of immunotherapy innovation. In general, the development of NK cell-directed therapies has two main focal points: optimizing the source of therapeutic NK cells for adoptive transfer and enhancing NK cell cytotoxicity and persistence in vivo. A wide variety of sources of therapeutic NK cells are currently being tested clinically, including haploidentical NK cells, umbilical cord blood NK cells, stem cell-derived NK cells, NK cell lines, adaptive NK cells, cytokine-induced memory-like NK cells and chimeric antigen receptor NK cells. A plethora of methods to augment the cytotoxicity and longevity of NK cells are also under clinical investigation, including cytokine-based agents, NK cell-engager molecules and immune-checkpoint inhibitors. In this Review, we highlight the variety of ways in which diverse NK cell products and their auxiliary therapeutics are being leveraged to target human cancers. We also identify future avenues for NK cell therapy research.

Original languageEnglish (US)
Pages (from-to)85-100
Number of pages16
JournalNature Reviews Clinical Oncology
Issue number2
StatePublished - Feb 2021

Bibliographical note

Publisher Copyright:
© 2020, Springer Nature Limited.


Dive into the research topics of 'Exploring the NK cell platform for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this